Abstract: Induced pluripotent stem (iPS) cells represent a powerful source for cell-based tissue regeneration because they are patient-specific cells and can differentiate into specialized cell types. Previously, we have demonstrated the derivation of neural crest like cells from iPS cells (iPS-NCLCs), and these cells have the potential to diff erentiate into dental mesenchymal cells, which subsequently diff erentiate into odontoblasts and dental pulp cells. In this study, we show that iPS-NCLCs can diff erentiate into mesenchymal stem cells (iPS-NCLC-MSCs), which contribute to craniofacial bone regeneration. iPS-NCLCs were cultured in serum-containing media and diff erentiated into functional MSCs, as confi rmed by expression MSC markers and their ability to diff erentiate into osteoblasts, adipocytes, and chondrocytes in vitro. iPS-NCLC-MSCs were negative for markers of undiff erentiated iPS cells and did not develop into teratomas when transplanted to immunodefi cient mice. Further, iPS-NCLC-MSCs grew normally and diff erentiated into osteoblasts on hydroxyapatite scaff olds in vitro. To assess the potential of iPS-NCLC-MSCs to regenerate craniofacial bone in vivo, iPS-NCLC-MSCs were transplanted into critical-size calvarial defects in immunodefi cient mice for 8 weeks. Histological analysis revealed that iPS-NCLC-MSCs diff erentiated into osteoblasts and contributed to bone regeneration without tumor formation. These results indicate that iPS-NCLC-MSCs could be a potential candidate for cell-based craniofacial bone tissue repair and regeneration.
Introduction
Numerous approaches have been proposed for bone defect repair and regeneration. To date, autogenous bone grafting of defects have been regarded as the "gold standard" because it has osteoconductive and osteoinductive properties and is a source of osteoprogenitor cells 1).
However, harvesting bone grafts often has disadvantages, including limited availability and donor site morbidity, additional surgery under general anesthesia, and risk of postoperative pain 2, 3) . Further, because allogeneic and xenogeneic grafts also have limited utility owing to the risks of immune rejection and infectious disease 4) , alternative treatment approaches would be advantageous. To overcome these limitations, bone tissue engineering using stem cells has recently attracted wide attention and shows promise in treating bone defects and avoiding bone graft problems.
In recent years, multipotent mesenchymal stem cells (MSCs), which can be isolated from adult tissues, have emerged as a promising cell source for tissue regeneration including bone. MSCs have been shown to possess a self-renewal capacity and the potential to diff erentiate into various mesenchymal cell lineages including osteoblasts, chondrocytes, and adipocytes, both in vitro and in vivo, as well as their potent paracrine anti-infl ammatory properties [5] [6] [7] . Conversely, there are factors that limit the routine use of adult tissue-derived MSCs for clinical treatment. For instance, the procedures involved in harvesting MSCs are invasive, expensive, and laborious. MSCs also have a limited proliferative and differentiation capacity that significantly decreases with age 8) , making it difficult to obtain the cell numbers required for transplantation [9] [10] [11] . Therefore, an alternative, unlimited source of MSCs derived from pluripotent stem cells in order to obtain larger populations would address these limitations.
Induced pluripotent stem (iPS) cells are generated by introducing defined transcription factors such as Sox2, Klf4, Oct3/4, and cMyc (called Yamanaka factors) into somatic cells, which have multipotential ability to diff erentiate into cell types characteristic of the 3 germ layers of embryonic stem cells (ESCs) in vitro and in vivo. This technology allows us to obtain pluripotent stem cells from patients' own cells and avoid the immune rejection and ethical issue of ESCs. Additionally, iPS cells off er an advantage over adult stem cells as they exhibit unlimited growth capacity as an inexhaustible stem cell source. Thus, iPS cells provide a powerful tool for stem cell-based regenerative medicine.
Recently, we have established a culture protocol to induce neural crest-like cells from iPS cells (iPS-NCLCs) and demonstrated that they have the potential to diff erentiate into dental mesenchymal cell-derived odontoblasts and dental pulp cells to form tooth structures 12, 13) . Based on results showing pluripotency of iPS-NCLCs, we hypothesized that iPS-NCLCs could diff erentiate into MSCs and become a suitable cell source for the regeneration of craniofacial bone that originates from neural crest-derived MSCs [14] [15] [16] . Toward this theory, we generated
MSCs from iPS-NCLCs (iPS-NCLC-MSCs) and evaluated their molecular characteristics and tumorigenicity. Then, the diff erentiation potential of iPS-NCLC-MSCs into osteoblasts was investigated in vitro. Finally, we created a calvarial defect model and assessed the effi cacy of iPS-NCLC-MSCs for bone regeneration in vivo. In the present study, we propose a novel stem cell source for personalized and functional craniofacial bone repair.
Materials and Methods

Antibodies
Anti-STRO-1, osteopontin (OP), fatty acid-binding protein (FABP), and collagen type II (Col2) antibodies were purchased from R&D systems (Minneapolis, MN). Anti-Gli-1, c-Myc, Osterix (OSX), and bone sialoprotein (BSP) antibodies were obtained from Abcam (Cambridge, U.K.). Anti-Osteonectin (ON) antibody was from Cosmo Bio (Tokyo, Japan). Anti-green fl uorescent protein (GFP) monoclonal antibodies were a product of Cell Signaling Technology (Danvers, MA). DAPI, Alexa Fluor 488, and Alexa Fluor 546 secondary antibodies were from Thermo Fisher Scientifi c (Tokyo, Japan).
Animals
The 8-week-old male KSN/Slc nude mice were obtained from Japan SLC, Inc. (Shizuoka, Japan) and maintained in plastic cages in ambient temperature of 23 ± 1°C with ad libitum access to water and a standard laboratory pellet diet. The experiments were conducted in accordance with the Protocols for the Humane Treatment of Animals of Iwate Medical University. The protocol of the animal experiment was approved by the Institutional Animal Care and Use Committee of Iwate Medical University, #27-044 and the Recombinant DNA Experiment Committee of Iwate Medical University, #389.
Cell culture and MSC induction
Mouse iPS cell line (iPS-MEF-Ng-20D-17, iPS-Stm-FB/gfp-99-1, iPS-Hep-FB/Ng/gfp-103C-1: RIKEN BRC, Japan) 17) were cultured on mitotically inactivated mouse embryonic fi broblasts in the culture medium: Dulbecco's modifi ed Eagle's medium (DMEM, Thermo Fisher Scientific, Waltham, MA) containing 15% fetal bovine serum (FBS), 0.1 mM non-essential amino acid (Thermo Fisher Scientifi c), 0.1 mM 2-Mercaptoethanol (Sigma-Aldrich, Tokyo, Japan), 50 U/ml and 50 µg/ ml Penicillin-Streptomycin (Thermo Fisher Scientific) supplemented with 1000 U/ml mouse leukemia inhibitory factor (LIF, Chemicon, Billerica, MA). The cultures were maintained at 37 °C in a 5% CO 2 humidifi ed incubator and the medium was changed every other day.
For iPS-NCLC-MSCs derived from iPS cells, we modified the previously described methods 12) . Briefly, iPS cells were dissociated by 0.25% Trypsin/EDTA and transferred to neural induction medium for suspension culture in a non-adherent culture dish (HydroCell, CellSeed, Tokyo, Japan) to form neuroectodermal spheres. The neural induction medium consisted of a 1:1 ratio of DMEM/F12 (Thermo Fisher Scientifi c) and Neurobasal Medium (Thermo Fisher Scientifi c) supplemented with 0.5 × N-2 (Thermo Fisher Scientific), 0.5 × B27 (Thermo Fisher Scientific), 5 µg/ml insulin (Sigma-Aldrich), 20 ng/ ml bFGF (R&D Systems), 20 ng/ml EGF (R&D Systems), and 50 U/ ml and 50 µg/ml Penicillin-Streptomycin. After 4 days of suspension culture, the spheres were transferred to a fibronectin-coated culture dish (BD Biosciences, San Jose, CA). After 8-10 days, the spheres or rosettes were manually dissected away and the resultant iPSNCLCs were passaged with 0.25% Trypsin-EDTA and replated on a fi bronectin culture dish. After checking the expression of NC marker as previously described 12) , iPS-NCLCs were cultured and maintained in DMEM containing 10% FBS and 50 U/ml and 50 µg/ml PenicillinStreptomycin on CorningTM PrimariaTM tissue culture dishes (Thermo Fisher Scientifi c) to induce MSCs. For iPS-NCLC-MSCs cultured on hydroxyapatite (HA), unidirectional porous HA scaffolds [18] [19] [20] (Kurarife, Kuraray Medical Inc., Tokyo, Japan) were coated with fi bronectin overnight at 4°C and washed with PBS 3 times. Dissociated iPS-NCLC-MSCs were seeded on the HA scaff olds and cultured in DMEM supplemented with 10% FBS for 2 days before osteoinduction.
Flow cytometric analysis
The cells were detached with 0.25% Trypsin-EDTA. For cellular staining, approximately 0.5-1 × 10 6 cells were incubated with PEconjugated primary antibody (anti-CD44, CD29, Sca-1, CD90.2, CD45, and CD11b; Miltenyi Biotec Inc., Auburn, CA,; BioLegend, San Diego, CA) for 30 min on ice. Cells were analyzed using a flow cytometer EPICS XL ADC (Beckman Coulter, Tokyo, Japan) and PERFLOW Sort V-4cTS2L (Furukawa Electric, Tokyo, Japan) with the accompanying software.
Immunostaining
Indirect immunostaining was performed on cultured cells and paraffin-embedded and frozen sections as previously described 12, 21) . After blocking with 5%, the cells and tissue sections were reacted with the above antibodies overnight at 4°C. After administration of secondary antibodies for 30 min, fluorescence images were obtained using a fluorescence microscope (IX71, BX51 Olympus) or laserscanning confocal microscope (FV300, Olympus). Control specimens were incubated directly with secondary antibodies in the absence of primary antibodies and processed as above. No significant positive immunoreactivity was found in controls. Image analyses were carried out using ImageJ or the software provided with the confocal microscope. All imaging data were obtained from experiments that were replicated at least 3 times.
Diff erentiation into mesenchymal lineage cells
Diff erentiation capacity of the iPS-NCLC-MSCs was investigated using the Mouse Mesenchymal Stem Cell Functional Identification Kit (R&D systems) according to the manufacturer's protocol. Briefl y, for osteogenic differentiation, cells were incubated in osteogenic differentiation medium for 3 weeks and detected by alizarin red staining and immunostaining of OP. For adipogenic differentiation, cells were incubated in adipogenic diff erentiation medium for 2 weeks and detected by oil red staining and immunostaining for FABP. For chondrogenic differentiation, cells were cultured in the conical tube with chondrogenic diff erentiation medium for 3 weeks to form pellets, which were fixed and prepared for frozen section for alcian blue staining and Col2 immunostaining.
Teratoma formation
We followed our previously described methods 12) in which undifferentiated iPS cells and iPS-NCLC-MSCs (1 × 10 6 cells) were mixed in type I-A collagen (500 µl) (Cellmatrix, Nitta Gelatin, Osaka, Japan) and were subcutaneously injected into the lower fl ank of agematched nude mice. The 4 mice injected with undifferentiated iPS cells and 4 mice injected with iPS-NCLC-MSCs were sacrifi ced after 4 weeks of cell injection.
Real-time RT-PCR
We followed our previously described methods 12, 21) in which Table 1 qRT-PCR Oligonucleotide Primers Used to Determine the Relative RNA Expression Level.
mRNA Orientation Sequence
Reverse 5'-TTGCTGTTGAAGTCGCAGGAG-3' total RNA was isolated using an RNeasy mini Kit (Qiagen, Tokyo, Japan) and reverse transcription of total RNA was performed using a PrimeScript RT reagent kit (Takara Bio, Siga, Japan). cDNA amplification was performed in quantitative reverse transcription polymerase chain reaction (qRT-PCRs) using SYBR® Premix Ex Taq™ (Takara Bio) with a Thermal Cycler Dice (Takara Bio) according to the manufacturer's protocol. Primer sequences for each cDNA are listed in Table 1 . Target gene expression levels were normalized based on GAPDH expression. The relative gene expression levels were calculated based on control culture levels using the comparative Ct (2− ΔΔCt) method. Experiments were carried out in triplicate.
Calvarial defects and surgical procedure We followed our previously described method 22) of using a trephine bar (Sophia Tech, Inc., Tokyo, Japan) and saline irrigation to create unilateral full-thickness calvarial defects (2.4 mm diameter) in the nonsuture-associated right and left parietal bone under general anesthesia. The dispersed GFP-expressing iPS-NCLC-MSCs (1 × 10 6 cells) were transplanted with β-tricalcium phosphate (β-TCP; OSferion®, Olympus, Tokyo, Japan) into the defects and the skin and periosteum were restored and sewed. As ≥2 mm was accepted as the critical size for the mouse calvarial defect 23) , we confirmed that a defect 2.4 mm in size irrigated using normal saline did not demonstrate significant radiographic or histological evidence of spontaneous healing after 12 weeks 22) .
Analysis of bone regeneration
Tissues from the original defect area of each group were fi xed in 4% PFA at 4°C overnight and decalcifi ed in 10% EDTA, and paraffi nembedded frontal cross-sections were made. Hematoxylin and eosin (H&E) staining was performed on every 10th section throughout the sample to examine the histological features in a detailed manner, and newly formed bone was evaluated for each group. Immunostaining for bone marker was performed as described above.
Statistics
All data are reported as mean ± SD. Statistical significance was assessed using two-tailed Student t tests for 2 groups or analysis of variance Tukey test for >2 groups. Signifi cance was defi ned as P < 0.05.
Results
Induction of diff erentiation from iPS cells to mesenchymal stem cells through neural crest like cells
Previously, we have established an efficient culture method for induction of neural crest-like cells derived from mouse iPS cells (iPSNCLCs) 12) . First, mouse iPS cells (Fig. 1A) were cultured in suspension for 4 days in neural crest induction medium to produce a neural sphere (Fig. 1B) . Next, the neural spheres spontaneously adhered to the bottom of the dish in 1-2 days and the rosette-like structures gave rise to stellate-morphology migratory cells (Fig. 1C and D) . The neural spheres were removed from the rosette, and the migratory cells were passaged and cultured (Fig. 1E) . The cells were positive for neural crest markers such as AP2-α, p75
NTR , and Wnt-1 12) , indicating neural crest cells. Subsequently, when the cells were cultured in serum-containing medium, they morphologically changed and exhibited a spindle shape like MSCs (Fig. 1F) . Immunocytochemistry showed that they were positive for MSC markers, Gli-1 (Fig. 1G ) and STRO-1 (Fig. 1H) . Flow cytometric analysis revealed that the cells were also positive for CD44 and CD29 and partially expressed Sca-1 and CD90.2 (Fig. 2) . In contrast, they were negative for CD45 and CD11b, leukocyte and macrophage markers, respectively (Fig. 2) , indicating that iPS-NCLCs are established as having a potential for diff erentiation into MSCs.
iPS-NCLC-MSCs lost tumorigenicity
We have previously demonstrated that iPS-NCLCs lost tumorigenicity in vivo, which undiff erentiated iPS cells possess 12) . Thus, in order to confirm that iPS-NCLC-MSCs also lost tumorigenicity, we implanted iPS-NCLC-MSCs subcutaneously into nude mice. Four weeks post-implantation, while undifferentiated iPS cells formed teratoma subcutaneously (Fig. 3 left) , iPS-NCLC-MSCs did not form any visible tumors (Fig. 3 right) . Quantitative PCR to examine the gene expression associated with maintaining an undifferentiated state and tumorigenicity revealed that Nanog, Lin28a, Oct3/4, and klf-4 were remarkably decreased in iPS-NCLC-MSCs compared to undiff erentiated iPS cells, while Sox2 was unchanged (Fig. 4) . Immunofluorescence showed that c-Myc was not expressed in iPS-NCLC-MSCs (data not shown). These results demonstrated that iPS-NCLC-MSCs induced from our culture protocol had no tumorigenicity.
iPS-NCLC-MSCs have the capacity to differentiate into multiple mesenchymal lineage cells
To verify the multipotency of iPS-NCLC-MSCs, in vitro diff erentiation into osteogenic, adipogenic, and chondrogenic lineages was performed using cell-lineage specific induction culture system. After 3 weeks of osteoinduction culture, mRNA expression of genes related to osteogenesis, such as OSX, bone morphogenetic protein 2 (BMP2), runt-related transcription factor 2 (Runx2), collagen type I, alpha 2 (Col1a2), and alkaline phosphatase (ALP) remarkably increased in osteoinduced iPS-NCLC-MSCs compared to undifferentiated iPS Figure 
Derivation of MSCs from iPS cells via neural crest cells. Morphological overview of MSCs derivation (A-F). miPS cells (A) were diff erentiated in suspension culture to form spheres (B), which spontaneously attached and formed rosette-like structures and stellate morphology cells migrating away in neural crest diff erentiation medium (C). Rosettes were removed (D) and the migrating cells formed a uniform cell population (E). The cells were then cultured in serum-containing medium and exhibited spindle-shaped morphology (F).
Immunofl uorescence of Gli-1 (G) and STRO-1 (H) in iPS-NCLC-MSCs. Scale bar = 200 µm (A-F), 20 µm (G), and 50 µm (H). Intensity cells (Fig. 5A) . Calcium deposition and OP expression were observed in iPS-NCLC-MSCs but not in cells in normal growth medium (Fig.  6A) . After 2 weeks adipogenic induction, iPS-NCLC-MSCs showed increased expression of peroxisome proliferator-activated receptor gamma (PPARγ) mRNA (Fig. 5B) , as well as positive staining for oil red O and FABP (Fig. 6B ). Chondrogenic diff erentiation was observed after culture as micromass pellets in medium containing chondrogenic supplements for 3 weeks. The pellets showed signifi cantly upregulated expression of Col2 mRNA (Fig. 5C ) and were alcian blue and Col2 positive (Fig. 6C) , verifying a chondrogenic character. In addition, to determine the specifi city of osteogenic induction of iPS-NCLC-MSCs, the mRNA expression of PPARγ and Col2 was evaluated in iPS-NCLCMSCs induced to osteogenesis. As expected, the expression of PPARγ and Col2 was not changed in osteogenic samples compared to iPS-NCLC-MSCs in normal growth medium (data not shown).
Osteogenic potential of iPS-MSC on hydroxyapatite
We also tried to verify the capability of iPS-NCLC-MSCs to differentiate into osteoblasts on hydroxyapatite (HA), the major inorganic component of bone. GFP-expressing iPS-NCLC-MSCs were seeded in fibronectin pre-coated unidirectional porous HA scaffolds (UDPHAp) (Fig. 7A ) and cultured for 2 days in normal growth media. Then the cells were cultured in osteoinduction media for 3 weeks. Immediately after seeding in the scaffold, the cells exhibited a round shape (Fig. 7Ba, arrows) . After 2 days, the cells attached and grew on the HA and exhibited a spindle shape under fluorescence microscopy ( Fig. 7Bb, arrows) . After 3 weeks of osteoinduction, immunocytochemistry revealed that OSX was expressed in GFPexpressing iPS-NCLC-MSCs (Fig. 7C, arrows) . OP was also distributed in the cells (Fig. 7D, arrows) and the edge of the scaffold (Fig. 7D,  arrowheads) , indicating that iPS-NCLC-MSCs could grow well and diff erentiate into osteoblasts on HA.
Osteogenic potential of iPS-NCLC-MSCs in vivo
To evaluate the osteogenic potential of iPS-NCLC-MSCs in vivo, GFP-expressing iPS-NCLC-MSCs were transplanted into criticalsize calvarial bone defects along with β-TCP and bone regeneration was assessed by histological observation. H&E staining showed newly formed osteoid tissues around β-TCP in iPS-NCLC-MSCs-transplanted calvarial defects 8 weeks after transplantation (Fig. 8A, arrows) whereas this was rarely seen in controls (Fig. 8B) . Immunohistochemistry demonstrated that the osteoid tissues were positive for OP, BSP, and ON (Fig. 8C) . Further, the GFP-positive cells around the osteoid tissues expressed OSX, indicating that iPS-NCLC-MSCs differentiated into osteoblasts (Fig. 8D) . Together, these results demonstrated that iPS-NCLC-MSCs had the potential to contribute to bone regeneration in vivo.
Discussion
With increasing interest in stem cell therapy for diseases that cause bone loss, it is fundamental to obtain a readily accessible and safe stem cell source with an osteogenic ability. To date, many types of stem cells such as MSCs and ESCs have shown great advanced potential for bone regeneration [24] [25] [26] . However, each cell has major drawbacks that are still unresolved and impeditive to clinical application. Consequently, development of a readily efficient method for deriving osteogenic cells from patients' iPS cells is necessary to overcome the limitation of such cells. In the present study, we demonstrated the craniofacial bone regeneration capacities of iPS-NCLC-MSCs from which a novel osteogenic cell source can be proposed for bone tissue engineering. 
GFP OSX Merge
The most reasonable way to perform efficient organ/tissue regeneration is to follow the sequential developmental step in vivo. Thus, specific stem cells based on developmental research can help achieve successful tissue regeneration. In craniofacial development, the cranial neural crest (NC) constitutes a major mesenchymal part of craniofacial tissues including bone 27, 28) . Indeed, a transgenic animal study using a lineage-tracing system experimentally showed that MSCs originated from NCs, and NC-derived cells resided in adult tissues with multipotent differentiation properties 14-16, 29, 30) . Based on the developmental feature of the craniofacial bone, we explored the potential contribution of iPS-NCLCs 12, 13) to craniofacial bone regeneration in this study. iPS-NCLCs cultured in serum-containing medium exhibited MSC phenotype expression of common MSC markers including Gli-1, craniofacial-specific MSC marker 31) , and the multipotency to differentiate into 3 mesenchymal cell lineages. These findings were consistent with previous reports demonstrating that NCs derived from human iPS cells have a capacity to diff erentiate into MSCs 32) . iPS-NCLC-MSCs can also be cryopreserved and retain differentiation and proliferation capacity in long-term culture. These results indicate that iPS-NCLC-MSCs can overcome the problem of somatic tissue-derived MSCs. Notably, since our culture protocol to induce NCs from mouse iPS cells was modified originally from that of human ESCs, which is virtually equivalent to iPS cells 33) , our protocol may be adaptable to human iPS cells. However, since detailed characteristics of derived iPS-NCLC-MSCs are still under investigation, further studies comparing the diff erence between iPS-NCLC-MSCs and somatic tissue-derived MSCs may provide more information to improve the effi ciency of induction protocol.
For clinical application of pluripotent stem cells in tissue regeneration, tumorigenesis must be the most taken into account. In the present study, we proved that iPS-NCLC-MSCs had no tumorigenicity in vivo. The safety of iPS-NCLC-MSCs further confi rmed the reduction of some pluripotency genes as shown in our previous study of iPSNCLCs 12) . Consistent with our results, recent studies related to MSCs derived from iPS cells have demonstrated their safety for clinical application 32, [34] [35] [36] , providing evidence to promote the use of iPS-NCLCMSCs for stem cell therapy. Interestingly, in iPS-NCLC-MSCs in the present study, Sox2 expression level was unchanged compared to that for undiff erentiated iPS cells. Sox2 not only regulates the self-renewal of ESCs and plays an important role in the maintenance of adult stem cells, but also closely relates to many types of cancer in several tissues such as lung, esophagus, and breast 37) . Sox2 also maintains the capability for expansion and diff erentiation of MSCs 38) . However, the role of Sox2 in the tumorigenesis of iPS cells is still unclear. In addition to Sox2, the relationship between other genes and tumorigenesis has been under debate. Zou et al. found that iPS-derived MSCs were positive for Nanog despite the exclusion of other pluripotent markers 34) . Lee et al. documented that polysialic acid-neural cell adhesion molecule (PSA-NCAM)-negative NC cells derived from human ESCs were tumorigenic 39) . These fi ndings suggest the importance and further necessity of basic and preclinical studies to evaluate the safety of the use of iPS cell-derived MSCs.
We further explored the possibility of clinical use of iPS-NCLCMSCs for craniofacial bone regeneration. First, we evaluated the engraftment and diff erentiation capacity of iPS-NCLC-MSCs on HA, the major mineral component of bone, and demonstrated that they exhibited the typical morphology of MSCs and could differentiate into osteoblasts by osteogenic induction. These results coincided with a previous study showing that MC3T3-E1 cells grew well on the UDPHAp surface 20) and suggested that iPS-NCLC-MSCs could maintain the differentiation capacity into osteoblasts on HA when transplanted. Second, we transplanted iPS-NCLC-MSCs with β-TCP in a calvarial defect and showed that the cells contributed to bone regeneration with no formation of tumor in vivo. In the implants, iPS-NCLC-MSCs expressed osteoblast marker genes, indicating that the cells could differentiate into osteoblasts and directly contribute to bone regeneration in vivo. Recent reports have also shown that adult MSCs have the capacity to secrete factors such as soluble extracellular matrix glycoprotein, cytokines, and growth factors to modulate the microenvironment and recruit resident cells to repair the degenerated tissue 40) . Thus, transplanted iPS-NCLC-MSCs in this study may also play a role in activating endogenous osteogenic progenitor cells by secretion of such factors.
Here, we showed the effi cient diff erentiation protocol from iPS cells into MSCs via NC induction, and that the iPS-NCLC-MSCs construct is promising to promote bone regeneration during calvarial bone repairs. Further study in other craniofacial implantation models such as periodontal and jawbone defects is required to validate its effi ciency. Also, the functionality for vascularization and mineralization to form better bone as well as the safety issues of tumorigenicity and immune rejection should be carefully evaluated in the long term. In addition to a tissue regeneration standpoint, as bone formation by iPS-NCLS-MSCs in this study follows the developmental steps of craniofacial bone, this could be used to aid in the understanding of normal craniofacial bone development mechanisms and become a powerful tool for disease modeling and drug discovery.
